Biotech Stocks To Research - November 10th

Key Points

• Seven biotech stocks flagged by MarketBeat’s high-dollar-volume screen: Moderna, PepGen, AbbVie, Danaher, Natera, Amgen, and argenx.
• Trading was mixed and volatile: Moderna fell $13.49 to $255.51, while PepGen rose $2.91 to $5.30 on unusually high volume; Natera and Amgen also declined.
• The companies span medicines, vaccines, diagnostics, and biotech tools, but the article notes that biotech investments can carry high risk because prospects may hinge on trial results, regulatory decisions, and research funding.

Moderna, PepGen, AbbVie, Danaher, Natera, Amgen, and argenex are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that use biological science to develop medicines, vaccines, diagnostics, or other health-related products. For investors, they can offer substantial growth potential but often carry high risk because a company’s prospects may depend on clinical-trial results, regulatory approvals, and its ability to fund research. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Shares of Moderna stock traded down $13.49 during trading on Tuesday, reaching $255.51. The company's stock had a trading volume of 4,986,856 shares, compared to its average volume of 12,611,287. The business's fifty day moving average price is $194.47 and its 200-day moving average price is $92.61. The firm has a market cap of $102.01 billion, a price-to-earnings ratio of -35.86 and a beta of 1.16. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. Moderna has a one year low of $22.28 and a one year high of $280.80.

Read Our Latest Research Report on MRNA

PepGen (PEPG)

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.

Shares of PEPG stock traded up $2.91 during mid-day trading on Tuesday, reaching $5.30. The company's stock had a trading volume of 80,050,734 shares, compared to its average volume of 1,376,396. The company has a market cap of $367.36 million, a P/E ratio of -4.02 and a beta of 2.02. PepGen has a 1-year low of $1.31 and a 1-year high of $7.80. The firm's 50-day moving average is $2.66 and its two-hundred day moving average is $2.98.

Read Our Latest Research Report on PEPG

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of AbbVie stock traded up $0.06 during mid-day trading on Tuesday, reaching $293.36. 937,579 shares of the stock were exchanged, compared to its average volume of 6,321,181. AbbVie has a fifty-two week low of $190.75 and a fifty-two week high of $302.93. The firm has a 50-day simple moving average of $272.71 and a 200 day simple moving average of $239.42. The company has a market cap of $518.55 billion, a price-to-earnings ratio of 50.46, a price-to-earnings-growth ratio of 1.34 and a beta of 0.20.

Read Our Latest Research Report on ABBV

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

DHR traded down $0.45 during midday trading on Tuesday, hitting $234.67. The company had a trading volume of 1,151,263 shares, compared to its average volume of 4,437,150. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.29 and a current ratio of 1.63. The firm's 50-day simple moving average is $220.65 and its 200-day simple moving average is $201.57. Danaher has a twelve month low of $160.93 and a twelve month high of $242.80. The company has a market capitalization of $165.10 billion, a PE ratio of 38.40, a P/E/G ratio of 2.95 and a beta of 0.76.

Read Our Latest Research Report on DHR

Natera (NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Shares of NTRA stock traded down $5.87 during trading hours on Tuesday, reaching $314.52. The company had a trading volume of 671,454 shares, compared to its average volume of 1,459,887. The company has a 50 day moving average of $380.13 and a 200 day moving average of $270.07. The firm has a market cap of $45.34 billion, a price-to-earnings ratio of -275.46 and a beta of 1.55. Natera has a 1-year low of $181.00 and a 1-year high of $437.41.

Read Our Latest Research Report on NTRA

Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

AMGN stock traded down $2.98 during trading hours on Tuesday, reaching $462.25. 376,523 shares of the stock were exchanged, compared to its average volume of 2,750,679. The firm's 50-day moving average is $423.08 and its 200-day moving average is $378.80. Amgen has a 12 month low of $312.39 and a 12 month high of $483.99. The company has a market cap of $249.91 billion, a price-to-earnings ratio of 26.80, a PEG ratio of 3.47 and a beta of 0.43. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.13.

Read Our Latest Research Report on AMGN

argenex (ARGX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Shares of NASDAQ:ARGX traded down $1.76 during trading on Tuesday, hitting $960.51. 178,894 shares of the company were exchanged, compared to its average volume of 352,372. The firm has a fifty day moving average price of $929.44 and a two-hundred day moving average price of $858.03. The stock has a market cap of $60.41 billion, a price-to-earnings ratio of 33.60, a P/E/G ratio of 0.86 and a beta of 0.48. argenex has a fifty-two week low of $661.85 and a fifty-two week high of $1,072.75.

Read Our Latest Research Report on ARGX

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.